Also known as: ATG Anti-thymocyte globulin
Antithymocyte immunoglobulin is a selective immunosuppressive agent mostly acting on T lymphocytes. Antithymocyte immunoglobulin is used for the prevention and treatment of graft rejection after solid organ transplantation, usually in combination with other immunosuppressive drugs.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Antithymocyte immunoglobulin is the active ingredient of these drugs:
Canada Estonia Hong Kong Ireland New Zealand
Austria Cyprus Estonia France Ireland
Brazil Ecuador France Ireland Lithuania